![conference banner](/images/conference-banner.jpeg)
Abstract
Bortezomib is the first proteasome inhibitor to be used clinically for the treatment of multiple myeloma and has been suggested as a possible treatment for a wide variety of hematologic and solid malignancies. Recent data suggests that potent immunomodulatory effects can also occur with systemic proteasome inhibition. This has been recently shown to occur in a graft-versus host disease model following bone marrow transplantation in mice. The suggested direct immunological effects of bortezomib treatment to include a decrease in anti-apoptotic protein levels, an increase in expression of TNF-family receptors (specifically Apo2L/TRAIL), induction of apoptosis, and inhibition of the transcription factor NF- κB. The NF- κB pathway has been associated with the regulation of numerous immune and inflammatory response mediators. In this review, we will present recent information concerning the potential therapeutic implications of bortezomib for a range of immune disorders. These findings would suggest that bortezomib treatment may be of clinical significance to suppress solid organ transplant rejection, autoreactive T cell responses, pro-inflammatory cytokine production, and consequently disease progression and pathology in autoimmunity.
Keywords: Autoimmunity, proteasome inhibition, bortezomib, multiple sclerosis, graft versus host disease, autoreactive T cell, transplantation
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Use of Systemic Proteasome Inhibition as an Immune-Modulating Agent in Disease
Volume: 7 Issue: 1
Author(s): Lauren H. Mattingly, Ruth A. Gault and William J. Murphy
Affiliation:
Keywords: Autoimmunity, proteasome inhibition, bortezomib, multiple sclerosis, graft versus host disease, autoreactive T cell, transplantation
Abstract: Bortezomib is the first proteasome inhibitor to be used clinically for the treatment of multiple myeloma and has been suggested as a possible treatment for a wide variety of hematologic and solid malignancies. Recent data suggests that potent immunomodulatory effects can also occur with systemic proteasome inhibition. This has been recently shown to occur in a graft-versus host disease model following bone marrow transplantation in mice. The suggested direct immunological effects of bortezomib treatment to include a decrease in anti-apoptotic protein levels, an increase in expression of TNF-family receptors (specifically Apo2L/TRAIL), induction of apoptosis, and inhibition of the transcription factor NF- κB. The NF- κB pathway has been associated with the regulation of numerous immune and inflammatory response mediators. In this review, we will present recent information concerning the potential therapeutic implications of bortezomib for a range of immune disorders. These findings would suggest that bortezomib treatment may be of clinical significance to suppress solid organ transplant rejection, autoreactive T cell responses, pro-inflammatory cytokine production, and consequently disease progression and pathology in autoimmunity.
Export Options
About this article
Cite this article as:
Mattingly H. Lauren, Gault A. Ruth and Murphy J. William, Use of Systemic Proteasome Inhibition as an Immune-Modulating Agent in Disease, Endocrine, Metabolic & Immune Disorders - Drug Targets 2007; 7 (1) . https://dx.doi.org/10.2174/187153007780059397
DOI https://dx.doi.org/10.2174/187153007780059397 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genistein: A Phytoestrogen with Multifaceted Therapeutic Properties
Mini-Reviews in Medicinal Chemistry Building Better Chimeric Antigen Receptors for Adoptive T Cell Therapy
Current Gene Therapy Tryptophan Catabolism in IDO+ Plasmacytoid Dendritic Cells
Current Drug Metabolism Properties and Therapeutic Potential of Transient Receptor Potential Channels with Putative Roles in Adversity: Focus on TRPC5, TRPM2 and TRPA1
Current Drug Targets Pericyte: Potential Target for Hemorrhagic Stroke Prevention and Treatment
Current Drug Delivery CD24 in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis: Targeting Redundancy for Immunotherapy?
Current Immunology Reviews (Discontinued) A Review on Possible Therapeutic Effect of Nigella sativa and Thymoquinone in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Cytochrome P450 in Neurological Disease
Current Drug Metabolism Targeting the Multifaceted HuR Protein, Benefits and Caveats
Current Drug Targets Human Papillomavirus (HPV) Vaccines as an Option for Preventing Cervical Malignancies: (How) Effective and Safe?
Current Pharmaceutical Design Pediatric Immune Dysfunction and Health Risks Following Early-Life Immune Insult
Current Pediatric Reviews Subject Index To Volume 2
Current Immunology Reviews (Discontinued) Disorders of Consciousness and Electrophysiological Treatment Strategies: A Review of the Literature and New Perspectives
Current Pharmaceutical Design Transcription Factors in Autoimmune Diseases
Current Pharmaceutical Design Functions of S100 Proteins
Current Molecular Medicine Recent Advances on the Roles of NO in Cancer and Chronic Inflammatory Disorders
Current Medicinal Chemistry Metallic Colloid Nanotechnology, Applications in Diagnosis and Therapeutics
Current Pharmaceutical Design Phosphonate Emerging Zinc Binding Group in Matrix Metalloproteinase Inhibitors
Current Drug Targets Induction of Regulatory T Cells by Dendritic Cells through Indoleamine 2,3- dioxygenase: A Potent Mechanism of Acquired Peripheral Tolerance
Current Medicinal Chemistry Recent advances in the management of autoimmune myocarditis: insights from animal studies.
Current Pharmaceutical Design